These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 35965001)
1. The tumor immune microenvironment in peritoneal carcinomatosis. Demuytere J; Ernst S; van Ovost J; Cosyns S; Ceelen W Int Rev Cell Mol Biol; 2022; 371():63-95. PubMed ID: 35965001 [TBL] [Abstract][Full Text] [Related]
2. Targeting the Tumor Microenvironment in Colorectal Peritoneal Metastases. Ceelen W; Ramsay RG; Narasimhan V; Heriot AG; De Wever O Trends Cancer; 2020 Mar; 6(3):236-246. PubMed ID: 32101726 [TBL] [Abstract][Full Text] [Related]
3. Established fibrous peritoneal metastasis in an immunocompetent mouse model similar to clinical immune microenvironment of gastric cancer. Fujimori D; Kinoshita J; Yamaguchi T; Nakamura Y; Gunjigake K; Ohama T; Sato K; Yamamoto M; Tsukamoto T; Nomura S; Ohta T; Fushida S BMC Cancer; 2020 Oct; 20(1):1014. PubMed ID: 33081727 [TBL] [Abstract][Full Text] [Related]
4. T-cell responses in colorectal peritoneal metastases are recapitulated in a humanized immune system mouse model. Saris J; Bootsma S; Verhoeff J; Tuynman JB; Wildenberg ME; Rijnstra ES; Lenos KJ; Garcia Vallejo JJ; Vermeulen L; Grootjans J Front Immunol; 2024; 15():1415457. PubMed ID: 39044825 [TBL] [Abstract][Full Text] [Related]
5. The role of the peritoneal microenvironment in the pathogenesis of colorectal peritoneal carcinomatosis. Demuytere J; Ceelen W; Van Dorpe J; Hoorens A Exp Mol Pathol; 2020 Aug; 115():104442. PubMed ID: 32305340 [TBL] [Abstract][Full Text] [Related]
6. Incidence, prognosis, and treatment options for patients with synchronous peritoneal carcinomatosis and liver metastases from colorectal origin. Thomassen I; van Gestel YR; Lemmens VE; de Hingh IH Dis Colon Rectum; 2013 Dec; 56(12):1373-80. PubMed ID: 24201391 [TBL] [Abstract][Full Text] [Related]
7. Altered intraperitoneal immune microenvironment in patients with peritoneal metastases from gastric cancer. Takahashi K; Kurashina K; Yamaguchi H; Kanamaru R; Ohzawa H; Miyato H; Saito S; Hosoya Y; Lefor AK; Sata N; Kitayama J Front Immunol; 2022; 13():969468. PubMed ID: 36119051 [TBL] [Abstract][Full Text] [Related]
8. Spheroid Formation and Peritoneal Metastasis in Ovarian Cancer: The Role of Stromal and Immune Components. Rakina M; Kazakova A; Villert A; Kolomiets L; Larionova I Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35682890 [TBL] [Abstract][Full Text] [Related]
9. Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases. Ripley RT; Davis JL; Kemp CD; Steinberg SM; Toomey MA; Avital I Trials; 2010 May; 11():62. PubMed ID: 20500867 [TBL] [Abstract][Full Text] [Related]
11. Management of colorectal cancer patients at high risk of peritoneal metastases. Shariff U; Seretis C; Youssef H J BUON; 2015 May; 20 Suppl 1():S71-9. PubMed ID: 26051336 [TBL] [Abstract][Full Text] [Related]
12. Peritumoral Immune-suppressive Mechanisms Impede Intratumoral Lymphocyte Infiltration into Colorectal Cancer Liver versus Lung Metastases. Ye J; Guo W; Wang C; Egelston CA; D'Apuzzo M; Shankar G; Fakih MG; Lee PP Cancer Res Commun; 2023 Oct; 3(10):2082-2095. PubMed ID: 37768208 [TBL] [Abstract][Full Text] [Related]
13. Cytoreduction and HIPEC in the treatment of "unconventional" secondary peritoneal carcinomatosis. Cardi M; Sammartino P; Mingarelli V; Sibio S; Accarpio F; Biacchi D; Musio D; Sollazzo B; Di Giorgio A World J Surg Oncol; 2015 Oct; 13():305. PubMed ID: 26493405 [TBL] [Abstract][Full Text] [Related]
14. The molecular biology of peritoneal metastatic disease. Bootsma S; Bijlsma MF; Vermeulen L EMBO Mol Med; 2023 Mar; 15(3):e15914. PubMed ID: 36700339 [TBL] [Abstract][Full Text] [Related]
15. Enhancing cancer-associated fibroblast fatty acid catabolism within a metabolically challenging tumor microenvironment drives colon cancer peritoneal metastasis. Peng S; Chen D; Cai J; Yuan Z; Huang B; Li Y; Wang H; Luo Q; Kuang Y; Liang W; Liu Z; Wang Q; Cui Y; Wang H; Liu X Mol Oncol; 2021 May; 15(5):1391-1411. PubMed ID: 33528867 [TBL] [Abstract][Full Text] [Related]
16. Intraperitoneal-Free Cancer Cells Represent a Major Prognostic Factor in Colorectal Peritoneal Carcinomatosis. Trilling B; Cotte E; Vaudoyer D; Isaac S; Piaton E; Maurice C; Glehen O; Passot G Dis Colon Rectum; 2016 Jul; 59(7):615-22. PubMed ID: 27270513 [TBL] [Abstract][Full Text] [Related]
17. An Efficient Prognostic Immune Scoring System For Colorectal Cancer Patients With Peritoneal Metastasis. Zhao Y; Chen C; Xu X; Ge X; Ding K; Zheng S; Wang J; Sun L Oncoimmunology; 2021 Mar; 10(1):1901464. PubMed ID: 33796414 [TBL] [Abstract][Full Text] [Related]
18. Treatment of peritoneal carcinomatosis of colorectal origin. Cercek A; Cusack JC; Ryan DP Am Soc Clin Oncol Educ Book; 2015; ():e208-11. PubMed ID: 25993175 [TBL] [Abstract][Full Text] [Related]
19. Cytoreductive surgery and HIPEC for peritoneal metastases combined with curative treatment of colorectal liver metastases: Systematic review of all literature and meta-analysis of observational studies. de Cuba EM; Kwakman R; Knol DL; Bonjer HJ; Meijer GA; Te Velde EA Cancer Treat Rev; 2013 Jun; 39(4):321-7. PubMed ID: 23244778 [TBL] [Abstract][Full Text] [Related]
20. Histological subtype and systemic metastases strongly influence treatment and survival in patients with synchronous colorectal peritoneal metastases. Simkens GA; Razenberg LG; Lemmens VE; Rutten HJ; Creemers GJ; de Hingh IH Eur J Surg Oncol; 2016 Jun; 42(6):794-800. PubMed ID: 27055946 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]